Series C financing will also be used for the development of Evox’s DeliverEX exosome drug platform
Series C financing will also be used for the development of Evox’s DeliverEX exosome drug platform
Funding will be given to four long COVID research studies
New data shows overuse of SABA relievers is responsible for 250,000 tonnes of CO2 emissions annually
Study is investigating company’s lead asset SFX-01
Extended indication in chronic heart failure authorised by the FDA
A growing number of patients are waiting 52 weeks or more for hospital treatment
Yuflyma is approved across 13 indications for the treatment of multiple chronic inflammatory diseases
Regulatory agency is asking for opinions on reclassifying the pills as pharmacy medications
Study is aiming to understand the role of genetic risk factors in patient responses to COVID-19
Antibody drug conjugate conditionally approved for HER2-positive metastatic breast cancer
Accelerate@Babraham supports early-stage life sciences ventures within the Babraham Research Campus’ community
CDK4 & 6 inhibitor has been available as part of a Cancer Drugs Fund (CDF) managed access agreement
CureVac’s CVnCoV is currently being investigated in a randomised, placebo-controlled Phase IIb/III clinical trial
People aged 65 to 69 and the clinically vulnerable will be offered the jab from today
The entry deadline for the 2021 International Clinical Researcher of the Year has been extended to the 16th of April.